Yong Fang

8PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 10, 2026
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

|May 27, 2026
Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer.

|Apr 17, 2026
Pyroptosis in cancer: a dual regulator of tumor cell fate and immune activation.

|Nov 27, 2025
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination.

Wenjian Gong, Zhiqi Liao, Fan Xiong

|Aug 13, 2025
Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer.

Xiaofei Jiao, Jiahao Liu, Yijie Wu

|May 30, 2025
LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.

Chunyan Song, Yaying Lin, Chujun Cai

Pageof 2

Frequent Collaborators

4 joint publications

Gordon B Mills

4 joint publications

Qinglei Gao

3 joint publications

Guangnian Zhao

3 joint publications

Li Zhu